Alvotech ALVO

NAS: ALVO | ISIN: LU2458332611   21/05/2025
10,16 USD (+3,89%)
(+3,89%)   21/05/2025

19 mei 2025 · Alvotech Appoints DNB Carnegie as Liquidity Provider on Nasdaq Stockholm · Persbericht

19 mei 2025 · Trading in Alvotech’s Shares on Nasdaq Stockholm Commences Today · Persbericht

16 mei 2025 · Alvotech Announces the Outcome of the Offering in Connection with the Company’s Listing on Nasdaq Stockholm · Persbericht

16 mei 2025 · Transactions of Managers and Closely Associated Persons · Persbericht

13 mei 2025 · Transactions of Managers and Closely Associated Persons · Persbericht

9 mei 2025 · Alvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada   · Persbericht

9 mei 2025 · Transactions of Managers and Closely Associated Persons · Persbericht

8 mei 2025 · Alvotech Publishes Prospectus in Connection with its Listing on Nasdaq Stockholm · Persbericht

7 mei 2025 · Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update · Persbericht

7 mei 2025 · Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech’s Product Revenues in 2025 · Persbericht

5 mei 2025 · Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab) · Persbericht

2 mei 2025 · Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14:00 CET) · Persbericht

27 maart 2025 · Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer · Persbericht

26 maart 2025 · Alvotech Reports Record Results for 2024 and Provides Business Update · Persbericht

26 maart 2025 · UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab) · Persbericht

20 maart 2025 · Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production · Persbericht

18 maart 2025 · Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® · Persbericht

7 maart 2025 · Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida · Persbericht

24 februari 2025 · Alvotech to Report Full Year Financial Results for 2024 on March 26, 2025, and Hosts Conference Call on March 27, 2025, at 8:00 am ET · Persbericht

21 februari 2025 · Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S. · Persbericht

Mijn selecties